# SABR for Renal Tumors

> **NCT03747133** · NA · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 45 (estimated)

## Conditions studied

- Renal Tumor

## Interventions

- **RADIATION:** Stereotactic Ablative Radiotherapy

## Key facts

- **NCT ID:** NCT03747133
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-11-01
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03747133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03747133, "SABR for Renal Tumors". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03747133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*